RxDoctor Payments Data

Joanne Waltman, MD

Internal Medicine · Festus, MONPI 1063692739

Payments from drug & device makers

$4,286in general payments, 2019–2025

Across 249 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$775
  • AstraZeneca$647
  • Novo Nordisk$458
  • GSK$421
  • Boehringer Ingelheim$216
  • Amgen$179
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$4,284100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,286 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$133,350
Medicare patients
380
Services billed
1,680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide91$177,310
TrulicityDulaglutide96$153,039
EliquisApixaban158$132,422
JardianceEmpagliflozin97$126,559
Trelegy ElliptaFluticasone/Umeclidin/Vilanter129$123,438
MounjaroTirzepatide41$60,341
FarxigaDapagliflozin Propanediol70$54,716
Soliqua 100-33Insulin Glargine/Lixisenatide40$40,318
JanuviaSitagliptin Phosphate32$36,137
AbrysvoRsv Vacc, Pref A And Pref B/Pf109$30,637
Tresiba Flextouch U-100Insulin Degludec20$21,914
MyrbetriqMirabegron24$21,762
Tresiba Flextouch U-200Insulin Degludec27$21,122
XareltoRivaroxaban31$18,892
Combivent RespimatIpratropium/Albuterol Sulfate24$18,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$775$213,380137 claims
Novo NordiskOzempic, Rybelsus$458$189,736103 claims
PfizerEliquis, Abrysvo$48$163,059267 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat$216$155,406141 claims
GSKTrelegy Ellipta$421$123,438129 claims
AstraZenecaFarxiga, Symbicort$647$66,699114 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$87$40,31840 claims
MerckJanuvia$95$36,13732 claims
Astellas Pharma US IncMyrbetriq$18$21,76224 claims
Johnson & JohnsonXarelto$55$18,89231 claims
AbbVieLinzess, Synthroid$116$13,80766 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Festus

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →